{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:34:55Z","timestamp":1715988895214},"reference-count":14,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T00:00:00Z","timestamp":1335139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background, objective\u2002<\/jats:bold> An international consensus conference underlined the importance of defining upper parathyroid hormone (PTH) reference values based on 25\u2010OH\u2010vitamin D [25(OH)D] to diagnose mild primary hyperparathyroidism. We determined the importance of this factor in a Belgian population.<\/jats:p><jats:p><jats:bold>Design, patients, methods\u2002<\/jats:bold> Intact PTH and 25(OH)D were measured in 261 healthy controls (18\u201365\u2003years, winter\/summer). They were classified as 25(OH)D replete (50\u2013153\u2003nmol\/l; <jats:italic>n<\/jats:italic>\u2003=\u2003129) or deplete (8\u201350\u2003nmol\/l; <jats:italic>n<\/jats:italic>\u2003=\u2003132). PTH was determined in 49 patients with surgically proven primary hyperparathyroidism. PTH thresholds for 95% specificities and corresponding sensitivities were computed from both 25(OH)D replete and deplete receiver operating characteristic (ROC) curves. The 95% bivariate reference ellipses, relating PTH to calcium for 25(OH)D replete and deplete controls, were compared to the PTH\/calcium pairs of patients with primary hyperparathyroidism.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Parathyroid hormone correlated with 25(OH)D (<jats:italic>r<\/jats:italic>\u2003=\u2003\u22120\u00b73232; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001). PTH normative values were 20% lower in 25(OH)D replete than deplete controls (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001). PTH thresholds, providing 95% specificities for primary hyperparathyroidism diagnosis, were 7\u00b76\u2003pmol\/l and 5\u00b78\u2003pmol\/l, using ROC curves derived from 25(OH)D deplete or replete controls, respectively. Corresponding sensitivities were of 56%<jats:italic>vs<\/jats:italic> 88%, respectively (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705). The 95% PTH\/calcium bivariate reference ellipses for?deplete and replete 25(OH)D controls differed, but the PTH\/calcium pairs of patients with primary hyperparathyroidism did not overlap these ellipses.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> For a given specificity, primary hyperparathyroidism diagnostic parathyroid hormone thresholds were lower and sensitivities higher using ROC curves, derived from 25(OH)D replete <jats:italic>vs<\/jats:italic> deplete controls. The 25(OH)D status does not affect the efficiency <jats:italic>of<\/jats:italic> primary hyperparathyroidism diagnosis, using bivariate PTH\/calcium reference density ellipses.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2011.04285.x","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T14:52:49Z","timestamp":1320763969000},"page":"785-789","source":"Crossref","is-referenced-by-count":15,"title":["Impact of vitamin D\u2010related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium\/PTH reference regions"],"prefix":"10.1111","volume":"76","author":[{"given":"Catherine","family":"Fill\u00e9e","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Marie","family":"Ketelslegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1758"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/clinchem\/33.8.1364","article-title":"Highly sensitive two\u2010site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia","volume":"33","author":"Nussbaum S.R.","year":"1987","journal-title":"Clinical Chemistry"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030097"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.12.2.137"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03894.x"},{"key":"e_1_2_7_7_2","first-page":"182","volume-title":"Tietz. Fundamentals of Clinical Chemistry","author":"Solberg H.E.","year":"1996"},{"key":"e_1_2_7_8_2","first-page":"1","volume-title":"Reference Values in Laboratory Medicine: The Current State of the Art","author":"Gr\u00e4sbeck R.","year":"1981"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/clinchem\/28.2.259","article-title":"The multivariate reference range: an alternative interpretation of multi\u2010test profiles","volume":"28","author":"Boyd J.C.","year":"1982","journal-title":"Clinical Chemistry"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2007.007091"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031979"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2340"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050162"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021266"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1760"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2011.04285.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2011.04285.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T23:22:01Z","timestamp":1698708121000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2011.04285.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,23]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1365-2265.2011.04285.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04285.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,23]]}}}